Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART: Metformin for Cerebrovascular Dysfunction in HIV and Metabolic Syndrome
NCT05571319Phase 2Completed
- Sponsor
- Stellenbosch University
- Start
- Aug 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of liquid metformin (Aspargo Labs) in cerebrovascular disease and endothelial dysfunction, sponsored by Stellenbosch University. Primary endpoints: Cerebral vascular reactivity at 12 weeks and Cerebral blood flow at 12 weeks. Started Aug 2022; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
cerebrovascular diseaseendothelial dysfunction
Beyond the preview
Go deeper on NCT05571319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05571319.